Johnson & Johnson Management

Management criteria checks 2/4

Johnson & Johnson's CEO is Joaquin Duato, appointed in Jan 2022, has a tenure of 2.92 years. total yearly compensation is $28.40M, comprised of 5.6% salary and 94.4% bonuses, including company stock and options. directly owns 0.015% of the company’s shares, worth CHF47.00M. The average tenure of the management team and the board of directors is 5 years and 5 years respectively.

Key information

Joaquin Duato

Chief executive officer

US$28.4m

Total compensation

CEO salary percentage	5.6%
CEO tenure	2.9yrs
CEO ownership	0.02%
Management average tenure	5yrs
Board average tenure	5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Joaquin Duato's remuneration changed compared to Johnson & Johnson's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 29 2024	n/a	n/a	US$15b
Jun 30 2024	n/a	n/a	US$16b
Mar 31 2024	n/a	n/a	US$17b
Dec 31 2023	US$28m	US$2m	US$13b
Oct 01 2023	n/a	n/a	US$12b
Jul 02 2023	n/a	n/a	US$12b
Apr 02 2023	n/a	n/a	US$11b
Jan 01 2023	US$13m	US$1m	US$16b
Oct 02 2022	n/a	n/a	US$18b
Jul 03 2022	n/a	n/a	US$17b
Apr 03 2022	n/a	n/a	US$20b
Jan 02 2022	US$14m	US$1m	US$18b
Oct 03 2021	n/a	n/a	US$18b
Jul 04 2021	n/a	n/a	US$18b
Apr 04 2021	n/a	n/a	US$15b
Jan 03 2021	n/a	n/a	US$15b
Sep 27 2020	n/a	n/a	US$17b
Jun 28 2020	n/a	n/a	US$15b
Mar 29 2020	n/a	n/a	US$17b
Dec 29 2019	US$13m	US$970k	US$15b
Sep 29 2019	n/a	n/a	US$14b
Jun 30 2019	n/a	n/a	US$16b
Mar 31 2019	n/a	n/a	US$15b
Dec 30 2018	US$9m	US$934k	US$15b
Sep 30 2018	n/a	n/a	US$2b
Jul 01 2018	n/a	n/a	US$1b
Apr 01 2018	n/a	n/a	US$1b
Dec 31 2017	US$19m	US$897k	US$1b

Compensation vs Market: Joaquin's total compensation ($USD28.40M) is above average for companies of similar size in the Swiss market ($USD4.69M).

Compensation vs Earnings: Joaquin's compensation has increased by more than 20% in the past year.

CEO

Joaquin Duato (61 yo)

2.9yrs

Tenure

US$28,397,240

Compensation

Mr. Joaquin Duato serves as Chief Executive Officer & Director of Johnson & Johnson since January 3, 2022 and serves as its Chairman since January 02, 2023. He served as Worldwide Chairman of Pharmaceutica...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Joaquin Duato	CEO & Chairman	2.9yrs	US$28.40m	0.015% CHF 47.0m
Joseph Wolk	Executive VP & CFO	6.4yrs	US$13.91m	0.0029% CHF 9.2m
Jennifer Taubert	Executive VP & Worldwide Chairman of Innovative Medicine	12.9yrs	US$11.00m	0.0064% CHF 20.0m
John Reed	Executive Vice President of Innovative Medicine	1.7yrs	US$20.65m	0.00061% CHF 1.9m
Robert Decker	Controller & Chief Accounting Officer	5yrs	no data	0.00082% CHF 2.5m
James Swanson	Executive VP & Chief Information Officer	5.1yrs	no data	0.00061% CHF 1.9m
Jessica Moore	Vice President of Investor Relations	3.1yrs	no data	no data
Dirk Brinckman	Chief Compliance Officer	no data	no data	no data
Elizabeth Forminard	Executive VP & Chief Legal Officer	2.2yrs	no data	0.00035% CHF 1.1m
Guy Lebeau	Group Chairman of MD&D Business - EMEA	no data	no data	no data
Kathryn Wengel	Executive VP and Chief Technical Operations & Risk Officer	6.4yrs	no data	0.0034% CHF 10.7m
Vanessa Broadhurst	Executive Vice President of Global Corporate Affairs	6.9yrs	no data	0.00082% CHF 2.5m

5.0yrs

Average Tenure

58yo

Average Age

Experienced Management: 000943981's management team is seasoned and experienced (5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Joaquin Duato	CEO & Chairman	2.9yrs	US$28.40m	0.015% CHF 47.0m
Anne Mulcahy	Independent Director	15.9yrs	US$410.00k	0.00034% CHF 1.1m
Hubert Joly	Independent Director	5yrs	US$320.00k	0.00021% CHF 652.3k
Marillyn Hewson	Lead Independent Director	5.7yrs	US$360.00k	0.00012% CHF 372.7k
Paula Johnson	Independent Director	1.8yrs	US$352.97k	0.000010% CHF 31.1k
Mark McClellan	Independent Director	11.2yrs	US$320.00k	0% CHF 0
Mary Beckerle	Independent Director	9.5yrs	US$355.00k	0% CHF 0
Darius Adamczyk	Independent Director	2.8yrs	US$340.00k	0.000040% CHF 124.2k
Jennifer Doudna	Independent Director	6.7yrs	US$320.00k	0% CHF 0
Eugene Woods	Independent Director	1.1yrs	US$89.15k	no data
Mark Weinberger	Independent Director	5yrs	US$340.00k	0.000040% CHF 124.2k
Nadja West	Independent Director	4yrs	US$340.00k	0% CHF 0

5.0yrs

Average Tenure

62.5yo

Average Age

Experienced Board: 000943981's board of directors are considered experienced (5 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 09:09
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/29
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Johnson & Johnson is covered by 62 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Toung	Argus Research Company
Ishan Majumdar	Baptista Research
Charles Butler	Barclays

Johnson & Johnson Management

Management criteria checks 2/4

Key information

Recent management updates

Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes

Recent updates

Johnson & Johnson to Report Q1, 2025 Results on Apr 15, 2025

Johnson & Johnson Announced New Results from the Phase 3 Cartitude-4 Study

Johnson & Johnson Announces Data from the Phase 3 Aquila Study

Johnson & Johnson Seeks U.S. FDA Approval for First Pediatric Indications for TREMFYA (Guselkumab)

Johnson & Johnson Seeks U.S. FDA Approval for Subcutaneous Induction Regimen of Tremfya (Guselkumab) inulcerative Colitis, A First for an IL-23 Inhibitor

Upcoming dividend of US$1.24 per share

Johnson & Johnson Announces Results from Additional Analyses of the Phase 2 DAHLIA Study Highlighting Improvement in Key Measures of Disease Activity and IgG Reduction

Johnson & Johnson Announces U.S. Food and Drug Administration Grants Nipocalimab Breakthrough Therapy Designation for the Treatment of Adults Living with Moderate-To-Severe Sjogren's Disease

Johnson & Johnson Submits Applications in the U.S. and EU Seek Approval of DARZALEX FASPRO® as Subcutaneous Monotherapy for High-Risk Smoldering Multiple Myeloma

Johnson & Johnson Announces Results from Phase 3 GRAVITI Study of Tremfya

Johnson & Johnson Highlights Innovative Neuropsychiatry Portfolio and Pipeline at Psych Congress

Johnson & Johnson Announces New Spectrem Study Findings Reveal Tremfya (Guselkumab) Effectively Clears Overlooked and Undertreated Plaque Psoriasis

Third quarter dividend of US$1.24 announced

Connecticut Jury Delivers $15 Million Asbestos Verdict Against Johnson & Johnson

Third quarter 2024 earnings released: EPS: US$1.11 (vs US$1.71 in 3Q 2023)

Johnson & Johnson Announces Positive Results from the Phase 2/3 Vibrance-MG Study of Nipocalimab

Johnson & Johnson Announces Tremfya Data in Both Crohn's Disease and Ulcerative Colitis

Johnson & Johnson Announces the Results of A Landmark Real-World, Head-To-Head Study Showing That Erleada (Apalutamide)

Johnson & Johnson Files for U.S. FDA Approval of DARZALEX FASPRO-Based Quadruplet Regimen for Newly Diagnosed Multiple Myeloma Patients for Whom Transplant Is Not Planned

Johnson & Johnson Announces Data from Three Studies Highlighting Clinical Efficacy of Darzalex® (Daratumumab) and Darzalex Faspro in Maintenance Regimens

Johnson & Johnson Announces Interim Data from the Ongoing Phase 2 Sunrise-4 Study Showing Neoadjuvant Treatment with Investigational Tar-200 Plus Cetrelimab

Johnson & Johnson Announces Updated Results from the Phase 3 Mariposa-2 Study Which Showed Rybrevant (Amivantamab-Vmjw)

Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes

Johnson & Johnson to Report Q4, 2024 Results on Jan 22, 2025

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources